Literature DB >> 20398098

Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?

Pornwalee Porapakkham1, Pramote Porapakkham, Henry Krum.   

Abstract

Beta-blockers (BBs) are mandatory therapy for patients with systolic chronic heart failure (CHF). However, it is uncertain whether target dose of these agents is more important than the achievement of target heart rate (HR) in maximizing the benefits of these agents. To test this, we obtained ECG absolute HR from patients with systolic CHF, together with consecutive left ventricular ejection fraction (EF) measures at least 3 months apart. Patients were divided into those who achieved target dose for beta-blocker and/or target absolute HR of < or = 60 beats per minute (bpm) and target change in HR (>10 bpm reduction) with increasing dose. Baseline ejection fraction (EF) was similar across all groups. Patients with absolute or change in HR at target achieved a greater change in EF than those not at target (P= 0.027 and P= 0.012, respectively). In contrast, those who achieved target dose did not achieve a significantly greater improvement in EF than those not at target dose (P= 0.81). Similarly for absolute EF, patients at target HR or target change in HR achieved a greater EF increase than those achieving target dose. Based on these data, target HR or change in HR appears to be more critical to improvement in EF than target dose in CHF patients. Therefore, achieving an absolute HR or change in HR with BBs may be more important than target dose in maximizing benefits of BBs in this setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20398098     DOI: 10.1111/j.1755-5922.2010.00136.x

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  9 in total

1.  CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.

Authors:  Jasmine A Luzum; Kevin M Sweet; Philip F Binkley; Tara J Schmidlen; Joseph P Jarvis; Michael F Christman; Wolfgang Sadee; Joseph P Kitzmiller
Journal:  Pharm Res       Date:  2017-02-08       Impact factor: 4.200

2.  Resting heart rate and real-life treatment modalities in outpatients with left ventricular systolic dysfunction study: A multicenter, prospective, observational, and national registry.

Authors:  Yüksel Çavuşoğlu; Ömer Kozan; Ahmet Temizhan; Mehmet Serdar Küçükoğlu
Journal:  Anatol J Cardiol       Date:  2021-05       Impact factor: 1.596

3.  Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?

Authors:  Jennifer Franke; Jan Sebastian Wolter; Lillian Meme; Jeannette Keppler; Ramon Tschierschke; Hugo A Katus; Christian Zugck
Journal:  Clin Res Cardiol       Date:  2012-07-04       Impact factor: 5.460

4.  Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy.

Authors:  Anna Corletto; Hanna Fröhlich; Tobias Täger; Matthias Hochadel; Ralf Zahn; Caroline Kilkowski; Ralph Winkler; Jochen Senges; Hugo A Katus; Lutz Frankenstein
Journal:  Clin Res Cardiol       Date:  2018-05-17       Impact factor: 5.460

5.  Relationships among achieved heart rate, β-blocker dose and long-term outcomes in patients with heart failure with atrial fibrillation.

Authors:  Robert J H Miller; Jonathan G Howlett; Michael H Chiu; Danielle A Southern; Merril Knudtson; Stephen B Wilton
Journal:  Open Heart       Date:  2016-12-23

6.  Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.

Authors:  Ify R Mordi; Bernadet T Santema; Mariëlle Kloosterman; Anna-Maria Choy; Michiel Rienstra; Isabelle van Gelder; Stefan D Anker; John G Cleland; Kenneth Dickstein; Gerasimos Filippatos; Pim van der Harst; Hans L Hillege; Marco Metra; Leong L Ng; Wouter Ouwerkerk; Piotr Ponikowski; Nilesh J Samani; Dirk J van Veldhuisen; Aeilko H Zwinderman; Faiez Zannad; Adriaan A Voors; Chim C Lang
Journal:  Clin Res Cardiol       Date:  2019-01-04       Impact factor: 5.460

7.  Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study.

Authors:  Katherine E Kurgansky; Petra Schubert; Rachel Parker; Luc Djousse; Jerome B Riebman; David R Gagnon; Jacob Joseph
Journal:  BMC Cardiovasc Disord       Date:  2020-02-26       Impact factor: 2.298

8.  Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases.

Authors:  Jianqiao Chen; Jin Zheng; Zifan Zhu; Benchuan Hao; Miao Wang; Huiying Li; Yulun Cai; Shiqi Wang; Jun Li; Hongbin Liu
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.810

9.  Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta-blockers.

Authors:  Kenneth D Varian; Xinge Ji; Justin L Grodin; Frederik H Verbrugge; Alex Milinovich; Michael W Kattan; W H Wilson Tang
Journal:  ESC Heart Fail       Date:  2020-08-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.